| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810823583 | 2018-07-25 | ||
| PCT/CN2019/097665WO2020020281A1 (en) | 2018-07-25 | 2019-07-25 | Anti-tigit antibody and uses thereof |
| Publication Number | Publication Date |
|---|---|
| SG11202100746WAtrue SG11202100746WA (en) | 2021-03-30 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100746WASG11202100746WA (en) | 2018-07-25 | 2019-07-25 | Anti-tigit antibody and use thereof |
| Country | Link |
|---|---|
| US (1) | US11370837B2 (en) |
| EP (1) | EP3838289A4 (en) |
| JP (2) | JP7524065B2 (en) |
| KR (1) | KR20210040827A (en) |
| CN (1) | CN112135626B (en) |
| AU (1) | AU2019310803B2 (en) |
| BR (1) | BR112021001201A2 (en) |
| CA (1) | CA3092456C (en) |
| SG (1) | SG11202100746WA (en) |
| TW (1) | TWI754157B (en) |
| WO (1) | WO2020020281A1 (en) |
| ZA (1) | ZA202100676B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| US20230080706A1 (en)* | 2020-01-21 | 2023-03-16 | Innovent Biologics (Suzhou) Co., Ltd. | Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof |
| CN111995681B (en)* | 2020-05-09 | 2022-03-08 | 华博生物医药技术(上海)有限公司 | anti-TIGIT antibody, preparation method and application thereof |
| CR20220611A (en) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | ANTI-TIGIT ANTIBODIES |
| KR20230024368A (en) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
| TW202216778A (en) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
| WO2022063100A1 (en)* | 2020-09-22 | 2022-03-31 | 南京圣和药业股份有限公司 | Anti-tigit antibody and double antibody and their application |
| CN114539405B (en)* | 2020-11-23 | 2024-02-23 | 广东菲鹏制药股份有限公司 | anti-TIGIT antibodies or antigen-binding fragments thereof |
| KR20220082776A (en)* | 2020-12-10 | 2022-06-17 | 주식회사 유틸렉스 | Anti-TIGIT Antibody and Use Thereof |
| AU2022267219A1 (en)* | 2021-04-26 | 2023-10-05 | Memorial Hospital For Cancer And Allied Diseases | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof |
| CN117916263B (en)* | 2021-05-10 | 2025-04-25 | 美帝马布生物公司 | Anti-TIGIT antibodies and uses thereof |
| JP2024527049A (en) | 2021-07-28 | 2024-07-19 | ジェネンテック, インコーポレイテッド | Methods and Compositions for Treating Cancer |
| CA3228504A1 (en)* | 2021-08-09 | 2023-02-16 | Tianhang ZHAI | Anti-tigit antibody and use thereof |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023108609A1 (en)* | 2021-12-17 | 2023-06-22 | Shanghai Nigene Biological Science And Technology Co., Ltd. | Tigit antibodies and uses thereof |
| CN120590537A (en)* | 2021-12-31 | 2025-09-05 | 南京维立志博生物科技股份有限公司 | Bispecific antibodies targeting TIGIT |
| KR20240144422A (en) | 2022-03-15 | 2024-10-02 | 컴퓨젠 엘티디. | IL-18BP antagonist antibodies and their uses in monotherapy and combination therapy for cancer treatment |
| KR20250006959A (en) | 2022-05-02 | 2025-01-13 | 아르커스 바이오사이언시즈 인코포레이티드 | Anti-TIGIT antibodies and uses thereof |
| KR20250022049A (en) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody |
| TW202515608A (en) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| DE68925966T2 (en) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
| GB9108652D0 (en) | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| ES2191016T3 (en) | 1992-09-16 | 2003-09-01 | Scripps Research Inst | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES FOR THE SYNCTIAL RESPIRATORY VIRUS. |
| JP3919830B2 (en) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | Anti-feline herpesvirus-1 recombinant antibody and gene fragment encoding the antibody |
| WO1995018634A1 (en) | 1994-01-04 | 1995-07-13 | The Scripps Research Institute | Human monoclonal antibodies to herpes simplex virus and methods therefor |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (en) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS. |
| GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| CN101088561A (en) | 1998-07-21 | 2007-12-19 | 展马博联合股份有限公司 | Anti-hepatitis C virus antibody and use thereof |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| SE526864C2 (en) | 2004-07-05 | 2005-11-15 | Svensk Roekgasenergi Intressen | Process and apparatus for separating pollutants from a gas stream |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| WO2006124667A2 (en) | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
| JP5933894B2 (en) | 2007-09-14 | 2016-06-15 | アディマブ, エルエルシー | Rationally designed synthetic antibody libraries and their use |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| PT2417156E (en) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| ES2439802T3 (en) | 2009-05-27 | 2014-01-24 | F. Hoffmann-La Roche Ag | Tri- or tetra-specific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
| HRP20201404T1 (en) | 2013-07-16 | 2020-11-27 | F. Hoffmann - La Roche Ag | PROCEDURES FOR THE TREATMENT OF CANCER USING PD-1 BASIC BINDING ANTAGONIST AND TIGIT INHIBITOR |
| LT3126394T (en) | 2014-03-31 | 2020-01-27 | F. Hoffmann-La Roche Ag | Anti-ox40 antibodies and methods of use |
| MD4733C1 (en)* | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anti-TIGIT antibodies |
| KR102644115B1 (en)* | 2014-12-23 | 2024-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies to tigit |
| TWI715587B (en)* | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit-binding agents and uses thereof |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AU2016307845B2 (en)* | 2015-08-14 | 2020-10-15 | Merck Sharp & Dohme Llc | Anti-TIGIT antibodies |
| CN108137691B (en) | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | Antibodies specific for human T-cell immunoglobulin and ITIM domain (TIGIT) |
| TWI811892B (en)* | 2015-09-25 | 2023-08-11 | 美商建南德克公司 | Anti-tigit antibodies and methods of use |
| DK3356413T3 (en) | 2015-10-01 | 2022-04-11 | Potenza Therapeutics Inc | ANTI-TIGIT ANTIGEN BINDING PROTEINS AND METHODS FOR USING IT |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| Publication number | Publication date |
|---|---|
| US11370837B2 (en) | 2022-06-28 |
| JP2024063083A (en) | 2024-05-10 |
| KR20210040827A (en) | 2021-04-14 |
| AU2019310803B2 (en) | 2022-11-03 |
| JP2021532058A (en) | 2021-11-25 |
| US20210040201A1 (en) | 2021-02-11 |
| AU2019310803A1 (en) | 2020-09-17 |
| CN112135626A (en) | 2020-12-25 |
| CA3092456A1 (en) | 2020-01-30 |
| BR112021001201A2 (en) | 2021-04-27 |
| TW202019465A (en) | 2020-06-01 |
| JP7524065B2 (en) | 2024-07-29 |
| WO2020020281A1 (en) | 2020-01-30 |
| CA3092456C (en) | 2024-03-12 |
| CN112135626B (en) | 2023-05-23 |
| EP3838289A1 (en) | 2021-06-23 |
| ZA202100676B (en) | 2023-10-25 |
| EP3838289A4 (en) | 2022-08-03 |
| TWI754157B (en) | 2022-02-01 |
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006904B (en) | Anti-il-4r antibody and use thereof | |
| SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
| IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
| IL268206A (en) | Bcma-targeting antibody and use thereof | |
| IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL287690A (en) | Anti-hvem antibodies and use thereof | |
| ZA202006255B (en) | Anti-pd-l1 antibody and use thereof | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
| IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
| IL282707A (en) | Anti-tim-3 antibodies and their use | |
| IL282708A (en) | Anti-tim-3 antibodies and their use | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| SG11202003585VA (en) | Anti-vista antibody and use thereof | |
| IL276548A (en) | Bcma-binding antibodies and uses thereof | |
| ZA201906248B (en) | Anti-ceacam1 antibody and use thereof |